<DOC>
	<DOCNO>NCT01442987</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety coadministered Irbesartan Atorvastatin patient hypertension hyperlipidemia .</brief_summary>
	<brief_title>Efficacy Safety Irbesartan Atorvastatin Hypertension Hyperlipidemia</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Irbesartan</mesh_term>
	<criteria>Aged 19 75 year Signed informed consent At screening , SPB ≥ 180mmHg DBP ≥ 110mmHg LDLC &gt; 250mg/dL TG ≥ 400mg/dL Has history hypersensitivity Angiotensin Ⅱ receptor blocker HMGCoA reductase inhibitor component drug Has history multidrug allergy</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Irbesartan</keyword>
	<keyword>Atorvastatin</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Hyperlipidemia</keyword>
</DOC>